Objectives Evidence on the safety and long-term efficacy of super selective bronchial artery embolisation (ssBAE) using platinum coils in patients with haemoptysis is insufficient. The objective of the present study was to evaluate the safety and the 3-year postprocedure haemoptysis-free survival rate of de novo elective ssBAE using platinum coils rather than particles for the treatment of haemoptysis.
Design A single-centre retrospective observational study.
Setting Hemoptysis and Pulmonary Circulation Center in Japan.
Participants A total of 489 consecutive patients with massive and non-massive haemoptysis who underwent de novo elective ssBAE without malignancy or haemodialysis.
Interventions ssBAE using platinum coils. All patients underwent CT angiography before the procedure for identifying haemoptysis-related arteries (HRAs) and for procedural planning.
Primary and secondary outcome measures The composite of the 3-year recurrence of haemoptysis and mortality from the day of the last ssBAE session. Each component of the primary end point and procedural success defined as successful embolisation of all target HRAs were also evaluated.
Results The median patient age was 69 years, and 46.4% were men. The total number of target vessels was 4 (quartile 2–7), and the procedural success rate was 93.4%. There were 8 (1.6%) major complications: 1 aortic dissection, 2 symptomatic cerebellar infarctions and 5 mediastinal haematoma cases. The haemoptysis-free survival rates were estimated by the Kaplan-Meier analysis at 86.9% (95% CI 83.7% to 90.2%) at 1 year, 79.4% (74.8% to 84.3%) at 2 years and 57.6% (45.1% to 73.4%) at 3 years. Although not statistically significant by the adjusted analysis of variance with multiple imputation of missing variables, cryptogenic haemoptysis tended to show the most favourable outcome and non-tuberculous mycobacterium showed the worst outcome (adjusted p=0.250).
Conclusions We demonstrated the safety and long-term efficacy of elective ssBAE using platinum coils and established that it can be a valuable therapeutic option for treating patients with haemoptysis.
- Bronchial artery embolization
- Computed tomography angiography
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Strengths and limitations of this study
The strengths of this study include the large sample size and standardiszed protocol of the elective super selective bronchial artery embolisation (ssBAE).
We could perform ssBAE safely with high success rates.
Our study is a single-centre, retrospective observational study.
Detailed information about the status of the underlying respiratory disorders of the patients who had an ssBAE could not be considered in the statistical analysis.
Haemoptysis is defined as airway bleeding and is a serious clinical complication, which can be fatal.1–6 There are essentially four treatment options for haemoptysis with respiratory and haemodynamic supports: drug therapy, bronchoscopic intervention, catheter intervention, such as bronchial artery embolisation (BAE), and lobectomy.1–6 BAE has been introduced on the basis of the rationale that one of the main causes of haemoptysis is a systemic–pulmonary shunt, such as a bronchopulmonary shunt, which results in lung vessel rupture;4–8 it has played an important role in emergent palliative haemostasis of massive haemoptysis for decades.5 ,6 Given the advancements in interventional devices and techniques, such as CT angiography, and since persistent sudden unexpected haemoptysis also severely impairs the patients' quality of life, more investigators have recently examined the use of BAE for long-term haemostasis.9–14 In fact, several reports have demonstrated improvements in long-term prognosis after BAE with polyvinyl alcohol (PVA) or N-butyl-2-cyanoacrylate (NBCA) when compared with gelatin sponges.10–14 However, since extreme caution should be exercised when using bloodstream-dependent embolisation materials, such as PVA or NBCA, controllable embolisation materials, such as metallic coils, can also be a candidate material for safe and effective BAE procedures in theory.10–15 Since little evidence is available on BAE with metallic coils, the aim of this study was to evaluate the safety and long-term (3-year) efficacy of elective super selective BAE (ssBAE) using platinum coils as the embolisation material with procedural planning based on CT angiography findings in patients with persistent haemoptysis retrospectively; we enrolled 489 consecutive patients at Eishinkai Hemoptysis and Pulmonary Circulation Center (EHPC) in Japan.
Study patients and data collection
Among the 533 consecutive patients with haemoptysis, who visited the EHPC from April 2010 to December 2015, 489 patients (696 procedures) with available outcome data who underwent de novo elective ssBAE were enrolled in this study. Haemoptysis was defined as airway bleeding with an estimated volume of >20 cc in each event. In this study, haemoptysis included both massive and non-massive haemoptysis. Approximately 20 mL of haemoptysis was the minimum required condition for candidates of ssBAE; however, the indication of ssBAE was made in a comprehensive manner, considering how severely haemoptysis impairs the patients' quality of life. Our typical candidates were patients who experienced persistent sudden unexpected haemoptysis, which severely impairs their quality of life regardless of the amount of haemoptysis. For example, most of them might hesitate to go shopping because they are constantly afraid of sudden unexpected haemoptysis in public. Thus, non-massive haemoptysis was also our target. Recurrence of haemoptysis was defined as haemoptysis of at least 20 mL as defined above, making patients opt to undergo another BAE due to severe impairment of their quality of life, because our goal was to completely eradicate the haemoptysis and because most patients underwent ssBAE for eventless daily life. Since the EHPC is basically an elective ssBAE centre and our objective in this study was to elucidate the efficacy of ssBAE for long-term haemostasis, we excluded emergency ssBAE. The reason for this is that the purpose of ssBAE is totally different between emergency and elective ssBAE at our institution. The main purpose of emergency ssBAE is rapid haemostasis to achieve haemodynamic and respiratory stability leaving aside a long-term efficacy. In contrast, the main purpose of elective ssBAE is to achieve long-term haemostasis to improve the quality of life of patients. Thus, exclusion of emergency ssBAE cases is needed to appropriately evaluate the long-term efficacy of elective ssBAE. Further, 32 patients with lung cancer and 6 patients with haemodialysis were also excluded because the impacts of malignancy or haemodialysis on the survival rate were assumed to be high, and we speculated that it is difficult to accurately evaluate the efficacy of ssBAE for long-term haemostasis in such patients (figure 1). We collected data on all the variables shown in tables 1 and 2 retrospectively from the patient records. The outcome data were collected using a variety of methods, including a review of patient records, phone conversation records between EHPC staff members and patients or family members, communication with other hospitals where the patients received follow-up care, or follow-up questionnaires sent from the EHPC to the participants. This study was supported by an independent Boston Scientific Corporation Investigator-Initiated Research Grant. Informed consent was obtained through the questionnaires. However, the requirement of written informed consent was waived because this study used retrospective data obtained mainly from the hospital records. Several cases have previously been published as case reports in another journal, and we obtained reprint permissions for the modified use of images from the journal (all images were modified and different from the original images).16
Identification of haemoptysis-related arteries
All of the patients underwent CT angiography with contrast medium enhancement before the procedure to evaluate the underlying causes of the haemoptysis, site of bleeding and possible haemoptysis-related arteries (HRAs) for procedural planning using 16-row multidetector CT (SIEMENS SOMATOM Emotion 16).5 ,6 ,9 ,17 The scan parameters were as follows: collimation 1.6×1.2 mm; tube voltage 130 kV; the tube current was determined by the CARE Dose4D system according to the patient's physique and ranged from 20 to 345 mA; rotation time 600 ms; pitch 1.2 mm; slice thickness 1.5 mm and reconstructed increment 0.70 mm. We tried to determine all possible HRAs with the CT angiography screening by using three-dimensional reconstructed images (figure 2). The three-dimensional images were reconstructed using 1.5 mm diameter slices, using the Ziostation 2 classic S V.22.214.171.124 (Zio soft, Tokyo, Japan). All of the CT angiography screenings were performed by highly experienced radiation technologists in a comprehensive manner. We identified several previously reported findings as signs of possible HRA as shown in figure 2. These consisted of dilation of the vessels as compared with the normal size for that site, tortuosity of the vessels, direct shunting of the vessels, aneurysmal formation, pleural adhesion with intercostal artery invasion into the lungs and ground glass opacity, suggesting inhaled blood, although some of these signs were only identified in select cases.1 ,5 ,6 ,8 ,9 The candidate HRAs included arteries related to the (1) aorta, for example, bronchial, intercostal, pulmonary ligament and inferior phrenic arteries; (2) subclavian artery, for example, internal thoracic, supreme intercostal and inferior thyroid arteries; and (3) axillary artery, for example, lateral thoracic, thoracoacromial and dorsal scapular arteries.1 ,5 ,6 ,8 ,9
Standard protocol of ssBAE
All of the ssBAE procedures were performed by highly experienced interventional pulmonologists, who are respiratory physicians undertaking at least 50 interventional radiology procedures annually. Our standard ssBAE protocol required two approach routes. The ssBAE for the aorta-related HRAs was performed via a transfemoral approach, and that for the subclavian-related and axillary-related HRAs was performed via a transradial or transbrachial approach. The number and approach sites of the ssBAE sessions were determined on the basis of the attending physician's discretion, after taking into consideration the condition of the patient and the possible HRAs suggested by the CT findings. All possible HRAs identified with CT were super selectively evaluated using arteriography with 5 Fr guiding catheter and 3 Fr microcatheter systems with 0.014 or 0.016-inch guide wires during the session. Aortography was not performed in general. When abnormal findings were observed, such as systemic–pulmonary shunts, proliferations of the capillary vessels or extravasation of the contrast medium to the lung tissues, they were super selectively embolised using the 3 Fr microcatheter system. The embolic materials used in all cases were platinum detachable or pushable coils (IDC or Interlock or VortX Boston Scientific Japan, Target Stryker Japan, Nester Cook Japan, C-STOPPER PIOLAX). The standard coil deployment manoeuvre is shown in figure 3. We attempted to embolise each HRA by using ≤3 platinum coils whenever possible, considering the insurance cost limitation in Japan. NBCA and gelatin sponges were used in several cases as a subsidiary treatment on a trial basis. Our speculation for these subsidiary treatments was that preocclusion with gelatin sponges may reduce the number of coils needed for embolisation or that postcoiling NBCAs may improve the long-term haemostatic effect after ssBAE. PVA was not used because it was not covered by the medical insurance in Japan during the study period. Procedural success was defined as successful embolisation of all target HRAs during the ssBAE sessions, and failure of even one HRA embolisation was considered a procedural failure.
The primary end point was the composite of the 3-year recurrence of haemoptysis and mortality from the day of the last ssBAE session. Secondary end points were the 3-year recurrence-free haemoptysis rate and 3-year survival rate. The patients who were alive were censored at the time of their last follow-up. Continuous variables were summarised using medians and IQRs (quartiles 1–3) and categorical variables using means of counts and percentages. The Kaplan-Meier analysis was employed to estimate the incidence of each end point, and the adjusted analysis of variance (ANOVA) was used to test the differences among the underlying diseases. The ANOVA was assessed using the multivariable Cox proportional hazard regression model. We used the following variables as covariates in the adjusted ANOVA with multiple imputation of missing variables: age, sex, body mass index, current smoking, ssBAE approach and total number of target vessels. All statistical tests were two-sided, with an α level of 0.05 considered statistically significant. All statistical analyses were performed using the R software packages (V.3.2.1; R Development Core Team).
In this study, 489 consecutive patients with a total of 696 ssBAE procedures were retrospectively analysed. The patient characteristics are summarised in table 1. The median patient age was 69 years, and 46.4% were men. Table 2 details the procedural information. The number of ssBAE sessions was one in 58.9% of all study patients, two in 39.9% and three in 1.2%. The average number of target vessels was 4 (2–7). The total procedural success rate was 93.4%, and the remaining 6.6% failed mainly due to one vessel embolisation failure because of the difficulty in embolising the ectopic bronchial artery derived from the underline part of the aortic arch. There were only 8 (1.6%) major complications: 1 aortic dissection, 2 symptomatic cerebellar infarctions and 5 mediastinal haematoma cases. Aortic dissection occurred in a patient with abdominal aortic aneurysm during the guiding catheter manipulation for intercostal arteriography. We speculated that the main cause of this complication was aortic wall fragility. One case of cerebellar infarction occurred during the supreme intercostal arteriography via the femoral approach, possibly because of atheromatous debris embolisation in the vertebral artery derived from the tip of the catheter. This could be avoided with the transradial approach. The other case of cerebellar infarction occurred after the procedure; its possible mechanism included thrombus embolisation derived from the proximal part of the embolised supreme intercostal and internal mammary arteries. Thus, coil embolisation cases near the vertebral artery need careful attention. In addition, mediastinal haematoma was addressed by haemostasis with platinum coil embolisation of the proximal arteries. Figure 2 shows the representative cases with three-dimensional CT and angiographic findings of the HRA before and after ssBAE.
There were 57 cases of recurrent haemoptysis and 23 deaths in this study. Figure 4 details the Kaplan-Meier estimates for each end point. The haemoptysis-free survival rates were 86.9% (95% CI 83.7% to 90.2%) at 1 year, 79.4% (74.8% to 84.3%) at 2 years and 57.6% (45.1% to 73.4%) at 3 years. Five deaths were associated with haemoptysis, five were due to the exacerbation of underlying diseases, five due to pneumonia and eight due to unknown causes. Although it was not statistically significant, cryptogenic haemoptysis tended to show the most favourable outcome, while non-tuberculous mycobacterium (NTM) had the worst outcome (adjusted ANOVA p=0.250). The recurrence-free haemoptysis rates were 90.4% (87.6% to 93.3%) at 1 year, 85.9% (82.1% to 89.9%) at 2 years and 67.7% (55.5% to 82.6%) at 3 years. The survival rates were 96.2% (94.3% to 98.0%) at 1 year, 93.3% (90.3% to 96.4%) at 2 years and 91.8% (88.2% to 95.5%) at 3 years.
In this study, we demonstrated the safety and long-term efficacy of elective ssBAE using platinum coils in a comprehensive manner by enrolling 489 patients with 696 procedures.10–15 The large sample size and standardised protocol for the elective ssBAE allowed us to clearly evaluate the influence of ssBAE, using platinum coils, on persistent haemoptysis. The safety and long-term efficacy of ssBAE using platinum coils were comparable with the results achieved using other materials for ssBAE, such as PVA or NBCA.10–14 Since only a little evidence on ssBAE using platinum coils was previously available, our study provides physicians with new insights into this field.15 We believe that our data will contribute to advancements in the treatment of patients with haemoptysis which severely impairs the patients' quality of life.
The rationale for using BAE is that one of the main causes of haemoptysis is the placement of a systemic–pulmonary shunt. Four available materials are typically used for embolising HRAs.4–8 The most conventional and popular embolisation material is the gelatin sponge. It is still often employed since it is quite inexpensive and easy to use; however, its effectiveness is usually limited and temporal owing to resorption.5 ,6 ,12 To overcome this limitation, PVA and NBCA have been introduced. In particular, the long-term efficacy of NBCA is impressive.13 ,14 However, it should be emphasised that extreme caution should be exercised when using liquid embolisation materials, such as NBCA, owing to the risk of misembolisation, particularly in the spinal branches, if the interventionist is not sufficiently experienced.5 ,6 ,13 ,14 ,18 ,19
In contrast, the unique aspect of our standard protocol for ssBAE is that we used platinum coils for the embolisation material.15 At this point, platinum coils are not typically used for BAE; they are used most often in very specific situations, such as pulmonary arteriovenous malformations or Rasmussen aneurysms.20 ,21 While all embolisation materials have their pros and cons, we have found that using platinum coils makes it relatively easy to control the site of embolisation, when compared with blood flow dependent-type materials.5 ,6 In fact, our total procedural success rate was 93.4% with only a 1.6% major complication rate, suggesting a consistent, secure and controlled coil implantation. These excellent procedural results were partly because of the very high visibility of the platinum coils under fluoroscopic guidance. Although some authors have reported that metallic coil embolisation can occlude more proximal vessels and may preclude repeat embolisation if haemoptysis recurs,5 ,6 ,20 ,21 we can perform ssBAE repeatedly to embolise HRAs just proximal to the previously occluded site when haemoptysis recurs (refer to the remaining proximal vessels of the HRAs in figure 2C, F, I). We believe that compared with the linear liquid embolisation of bloodstream-dependent materials, pinpoint embolisation of platinum coils contributes to the controllable HRA embolisation. Detachable coils are a good option for inexperienced interventional pulmonologists, whereas liquid-type material embolisation cannot be retried. Further, authors especially find the utility of detachable coils in cases where the backup force of guiding catheters is insufficient. In this case, it is difficult to deploy the coil in the target site because the position of the microcatheter cannot be fixed easily, and retractions may be needed several times. Even though it is difficult to discuss issues on the cost-effectiveness of ssBAE in detail because the cost and standard procedures may be different among institutions, the primary disadvantage of metallic coils for ssBAE is their cost, especially with detachable coils. However, this problem could be resolved with the increased use of pushable platinum coils for ssBAE by experienced interventionists, since the cost is one-fourth that of detachable coils. Cost-effectiveness, as well as the risks and benefits, should be determined by each physician depending on their experiences.
In this study, we showed that the haemoptysis-free survival rates were 86.9% (83.7% to 90.2%) at 1 year, 79.4% (74.8% to 84.3%) at 2 years and 57.6% (45.1% to 73.4%) at 3 years. Even though we should interpret these data with caution since patient prognoses may differ depending on their underlying diseases, the procedural outcomes were favourable and comparable with those of other ssBAE materials, such as PVA or NBCA.10–14 For example, Woo et al14 reported that the 1-year and 3-year haemoptysis-free survival rates of ssBAE with PVA (n=293) were 77% and 68%, respectively, and those with NBCA (n=113) were 88% and 85%, respectively, in one of the largest retrospective observational studies.
We also determined that cryptogenic haemoptysis tended to show the most favourable outcome, whereas NTM tended to show the worst outcome, although these differences were not statistically significant. These findings were consistent with those of previous experimental reports, which suggested prognostic differences for haemoptysis depending on the underlying diseases. For example, several studies reported worse outcomes in patients with chronic tuberculosis or aspergillosis.5 ,10 ,11 ,14
Recurrence of haemoptysis after BAE can be caused pathomechanically by incomplete embolisation, recanalisation of the embolised bronchial artery, collateralisation by other arterial vascular territories, missed culprit vessel identification, inadequate causal therapy or progression of the underlying pulmonary disease.5 ,6 Evaluation of the mechanisms of recurrent haemoptysis after ssBAE using metallic coils and identification of preventive strategies for recurrent haemoptysis are additional clinical questions that require further studies.
At any rate, selective coil embolisation should be considered as one of the first-line options for haemoptysis rather than being viewed as inferior to particle embolisation considering its long-term efficacy and safety to avoid non-target tissue necrosis owing to the controllability of embolisation of detachable coils.
There are several study limitations that should be mentioned. First, it was difficult to objectively evaluate the amount of haemoptysis retrospectively because data on the severity of haemoptysis were not collected in a uniform quantitative manner.3 Second, the control of the patients' underlying respiratory disorders also influenced their prognosis. Since many of the study patients were medically managed by attending pulmonologists at outside facilities and were referred to our institution specifically to undergo elective ssBAE, detailed information about the status of their respiratory disorders was not available in this study.6 Third, there are criticisms that non-massive haemoptysis should not be treated using ssBAE because some physicians express concern about the safety and lack of evidence of its long-term efficacy. However, we believe that attending pulmonologists can understand how sudden unexpected haemoptysis impairs the patients' quality of life even though it is non-massive. Attending physicians should understand how the extrication from persistent unexpected haemoptysis can be valuable for these patients. All patients in this study accepted the risk of major complications. Fourth, some procedure-related information, such as procedural time, was not available during the study period, although the median procedural time was 113 min recently. Fifth, the definition of major complications varies among studies; however, we employed the definition from the guideline of the Society of Interventional Radiology Standards of Practice Committee.22 Finally, our study is a single-centre, retrospective observational study. Our data should be interpreted considering these limitations.
We demonstrated the safety and long-term efficacy of elective ssBAE using platinum coils. ssBAE using platinum coils can be a valuable therapeutic option for treating patients with haemoptysis.
The authors express their gratitude to Dr Seiei Shirakawa, the president of Kishiwada Eishinkai Hospital, Unshow Shirakawa, the vice president, and the Japan Society of Clinical Research for their dedicated support for our works.
Contributors HI, MH and MR had full access to all of the study data and take responsibility for the integrity of the data and accuracy of the data analysis, including and especially any adverse effects. HI, MH, MR, JT, MY, MA, YN, DK, KY and AS contributed substantially to the study design, data analysis and interpretation, and to the writing and final approval of the manuscript.
Funding This study was supported by an independent Boston Scientific Corporation Investigator-Initiated Research Grant.
Competing interests None declared.
Ethics approval The study protocol complied with the Helsinki Declaration standards and was approved by the Ethical Committee of the EHPC (approval number 2012–02).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.